MGF
- Category
- Tissue Repair & Recovery
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Synthetic MGF is an E-domain fragment associated with an IGF-1 splice variant expressed by stressed muscle, marketed to speed muscle, tendon, and heart repair. The case rests almost entirely on animal and cell studies; a 2014 study found no measurable activity, calling the mechanism into question. There is no human safety data, and as an IGF-1 relative it carries a theoretical cancer risk. Supply is unregulated black-market product of uncertain purity, and it is not an approved drug.
Read Full recordStudied uses & evidence
Studied uses(7)
Satellite cell activation and muscle repair
LowRodent studies suggest muscle activation signals. Human evidence includes gene-expression studies and experiments in cultured human muscle cells, with contradictory results.
Enhanced myogenic progenitor cell transplantation
SpeculativeImproved cell engraftment in one mouse transplantation study; not replicated or tested in humans.
Cardiac protection and post-infarction recovery
LowMultiple rodent heart-attack studies show benefit, with a plausible mechanism, but no human trials.
Evidence limits
- Evidence Level
- Preclinical
All MGF research to date is preclinical, conducted in cell cultures, rodent models, and one sheep cardiac model. No controlled human clinical trials have been conducted. Results are mixed: some labs report robust effects on satellite cell activation and cardiac protection, while a well-powered 2014 study found no significant effects on myoblasts or primary muscle stem cells. The existence of endogenous E-peptide processing in vivo has not been confirmed despite mRNA detection.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighMGF is a splice variant of IGF-1. Growth factor activity may promote tumor proliferation.
General cautions
Pregnancy
AbsoluteNo safety data. Growth factor signaling during fetal development is unpredictable.
Risk summary(10)
Risks = level of concern: High · Moderate · Low · Theoretical
No human safety data exists — all evidence is preclinical
HighEndogenous E-peptide processing has never been confirmed in vivo despite mRNA detection
ModerateMajor 2014 study found zero biological activity in multiple cell types, questioning the entire MGF hypothesis
HighIllegal MGF analogs of unknown purity and properties are sold on the black market with potentially serious side effects
HighAs an IGF-1 splice variant, theoretical oncogenic risk exists — IGF-1 signaling is implicated in cancer proliferation
TheoreticalMGF peptide may aggregate at physiological pH, making bioavailability and actual dose uncertain
TheoreticalInjection site reactions (pain, swelling, redness) reported anecdotally
LowPotential hypoglycemia risk given IGF-1 family membership, though not directly documented for MGF
TheoreticalLong-term effects of exogenous MGF administration are completely unknown
HighNo standardized manufacturing or quality control for commercially available MGF products
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.